Clinical and molecular biology findings have led to the identification of tumour overexpressing HER2 (HER2+) as a distinct subset (comprising 20–25%) of breast carcinomas (Slamon et al, 1989; Ross and Fletcher, 1998,1999; Ménard et al, 2002). Here, ERBB2 is linked to neoplasm.